[1] W.C. of T.E. Board, Soft Tissue and Bone Tumours, n.d. https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/Soft-Tissue-And-Bone-Tumours-2020 (accessed April 12, 2021).
[2] E.G. Demicco, A.M. Griffin, R.A. Gladdy, B.C. Dickson, P.C. Ferguson, C.J. Swallow, J.S. Wunder, W.L. Wang, Comparison of published risk models for prediction of outcome in patients with extrameningeal solitary fibrous tumour, HISTOPATHOLOGY. 75 (2019) 723–737. https://doi.org/10.1111/his.13940.
[3] D.N. Louis, A. Perry, G. Reifenberger, A. von Deimling, D. Figarella-Branger, W.K. Cavenee, H. Ohgaki, O.D. Wiestler, P. Kleihues, D.W. Ellison, The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary, Acta Neuropathol. 131 (2016) 803–820. https://doi.org/10.1007/s00401-016-1545-1.
[4] C. Bouvier, P. Métellus, A.M. de Paula, A. Vasiljevic, A. Jouvet, J. Guyotat, K. Mokhtari, P. Varlet, H. Dufour, D. Figarella-Branger, Solitary fibrous tumors and hemangiopericytomas of the meninges: overlapping pathological features and common prognostic factors suggest the same spectrum of tumors, Brain Pathol. 22 (2012) 511–521. https://doi.org/10.1111/j.1750-3639.2011.00552.x.
[5] D.R. Robinson, Y.-M. Wu, S. Kalyana-Sundaram, X. Cao, R.J. Lonigro, Y.-S. Sung, C.-L. Chen, L. Zhang, R. Wang, F. Su, M.K. Iyer, S. Roychowdhury, J. Siddiqui, K.J. Pienta, L.P. Kunju, M. Talpaz, J.M. Mosquera, S. Singer, S.M. Schuetze, C.R. Antonescu, A.M. Chinnaiyan, Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing, Nat Genet. 45 (2013) 180–185. https://doi.org/10.1038/ng.2509.
[6] S. Trabelsi, N. Mama, M. Chourabi, M.H. Mastouri, M. Ladib, S. Popov, A. Burford, M. Mokni, K. Tlili, H. Krifa, C. Jones, M.T. Yacoubi, A. Saad, D.H.-B. Brahim, Meningeal Hemangiopericytomas and Meningomas: a Comparative Immunohistochemical and Genetic Study, Asian Pac. J. Cancer Prev. 16 (2015) 6871–6876.
[7] M. Peyre, C. Salaud, E. Clermont-Taranchon, M. Niwa-Kawakita, S. Goutagny, C. Mawrin, M. Giovannini, M. Kalamarides, PDGF activation in PGDS-positive arachnoid cells induces meningioma formation in mice promoting tumor progression in combination with Nf2 and Cdkn2ab loss, Oncotarget. 6 (2015) 32713–32722. https://doi.org/10.18632/oncotarget.5296.
[8] M. Kawashima, S.O. Suzuki, T. Yamashima, M. Fukui, T. Iwaki, Prostaglandin D synthase (beta-trace) in meningeal hemangiopericytoma, Mod. Pathol. 14 (2001) 197–201. https://doi.org/10.1038/modpathol.3880285.
[9] C. Apra, K. Mokhtari, P. Cornu, M. Peyre, M. Kalamarides, Intracranial solitary fibrous tumors/hemangiopericytomas: first report of malignant progression, J. Neurosurg. (2017) 1–6. https://doi.org/10.3171/2017.1.JNS162593.
[10] O. Damodaran, P. Robbins, N. Knuckey, M. Bynevelt, G. Wong, G. Lee, Primary intracranial haemangiopericytoma: Comparison of survival outcomes and metastatic potential in WHO grade II and III variants, Journal of Clinical Neuroscience. 21 (2014) 1310–1314. https://doi.org/10.1016/j.jocn.2013.11.026.
[11] L. Schweizer, C. Koelsche, F. Sahm, R.M. Piro, D. Capper, D.E. Reuss, S. Pusch, A. Habel, J. Meyer, T. Göck, D.T.W. Jones, C. Mawrin, J. Schittenhelm, A. Becker, S. Heim, M. Simon, C. Herold-Mende, G. Mechtersheimer, W. Paulus, R. König, O.D. Wiestler, S.M. Pfister, A. von Deimling, Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein, Acta Neuropathol. 125 (2013) 651–658. https://doi.org/10.1007/s00401-013-1117-6.
[12] S. Yuzawa, H. Nishihara, L. Wang, M. Tsuda, T. Kimura, M. Tanino, S. Tanaka, Analysis of NAB2-STAT6 Gene Fusion in 17 Cases of Meningeal Solitary Fibrous Tumor/Hemangiopericytoma: Review of the Literature, Am. J. Surg. Pathol. (2016). https://doi.org/10.1097/PAS.0000000000000625.
[13] S. Barthelmeß, H. Geddert, C. Boltze, E.A. Moskalev, M. Bieg, H. Sirbu, B. Brors, S. Wiemann, A. Hartmann, A. Agaimy, F. Haller, Solitary fibrous tumors/hemangiopericytomas with different variants of the NAB2-STAT6 gene fusion are characterized by specific histomorphology and distinct clinicopathological features, Am. J. Pathol. 184 (2014) 1209–1218. https://doi.org/10.1016/j.ajpath.2013.12.016.
[14] R. Vogels, N. Macagno, K. Griewank, P. Groenen, M. Verdijk, J. Fonville, B. Kusters, French CNS SFT/HPC Consortium, Dutch CNS SFT/HPC Consortium, D. Figarella-Branger, P. Wesseling, C. Bouvier, U. Flucke, Prognostic significance of NAB2-STAT6 fusion variants and TERT promotor mutations in solitary fibrous tumors/hemangiopericytomas of the CNS: not (yet) clear, Acta Neuropathol. 137 (2019) 679–682. https://doi.org/10.1007/s00401-019-01968-3.
[15] C. Koelsche, F. Sahm, D. Capper, D. Reuss, D. Sturm, D.T.W. Jones, M. Kool, P.A. Northcott, B. Wiestler, K. Böhmer, J. Meyer, C. Mawrin, C. Hartmann, M. Mittelbronn, M. Platten, B. Brokinkel, M. Seiz, C. Herold-Mende, A. Unterberg, J. Schittenhelm, M. Weller, S. Pfister, W. Wick, A. Korshunov, A. von Deimling, Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system, Acta Neuropathol. 126 (2013) 907–915. https://doi.org/10.1007/s00401-013-1195-5.
[16] C. Mirian, A.K. Duun-Henriksen, T. Juratli, F. Sahm, S. Spiegl-Kreinecker, M. Peyre, A. Biczok, J.-C. Tonn, S. Goutagny, L. Bertero, A.D. Maier, M. Møller Pedersen, I. Law, H. Broholm, D.P. Cahill, P. Brastianos, L. Poulsgaard, K. Fugleholm, M. Ziebell, T. Munch, T. Mathiesen, Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysis, J. Neurol. Neurosurg. Psychiatry. 91 (2020) 378–387. https://doi.org/10.1136/jnnp-2019-322257.
[17] H.K. Park, D.B. Yu, M. Sung, E. Oh, M. Kim, J.-Y. Song, M.-S. Lee, K. Jung, K.-W. Noh, S. An, K. Song, D.-H. Nam, Y.J. Kim, Y.-L. Choi, Molecular changes in solitary fibrous tumor progression, J. Mol. Med. 97 (2019) 1413–1425. https://doi.org/10.1007/s00109-019-01815-8.
[18] Y. Morimitsu, M. Nakajima, M. Hisaoka, H. Hashimoto, Extrapleural solitary fibrous tumor: clinicopathologic study of 17 cases and molecular analysis of the p53 pathway, APMIS. 108 (2000) 617–625. https://doi.org/10.1034/j.1600-0463.2000.d01-105.x.
[19] M.M. Subramaniam, X.Y. Lim, K. Venkateswaran, C.S. Shuen, R. Soong, F. Petersson, Dedifferentiated solitary fibrous tumour of the nasal cavity: the first case reported with molecular characterization of a TP53 mutation, Histopathology. 59 (2011) 1269–1274. https://doi.org/10.1111/j.1365-2559.2011.03997.x.
[20] K. Akaike, A. Kurisaki-Arakawa, K. Hara, Y. Suehara, T. Takagi, K. Mitani, K. Kaneko, T. Yao, T. Saito, Distinct clinicopathological features of NAB2-STAT6 fusion gene variants in solitary fibrous tumor with emphasis on the acquisition of highly malignant potential, Hum. Pathol. 46 (2015) 347–356. https://doi.org/10.1016/j.humpath.2014.11.018.
[21] I. Machado, G.N. Morales, J. Cruz, J. Lavernia, F. Giner, S. Navarro, A. Ferrandez, A. Llombart-Bosch, Solitary fibrous tumor: a case series identifying pathological adverse factors-implications for risk stratification and classification, Virchows Arch. 476 (2020) 597–607. https://doi.org/10.1007/s00428-019-02660-3.
[22] A. Kurisaki-Arakawa, K. Akaike, K. Hara, A. Arakawa, M. Takahashi, K. Mitani, T. Yao, T. Saito, A case of dedifferentiated solitary fibrous tumor in the pelvis with TP53 mutation, Virchows Arch. 465 (2014) 615–621. https://doi.org/10.1007/s00428-014-1625-3.
[23] Y. Ono, K. Ueki, J.T. Joseph, D.N. Louis, Homozygous deletions of the CDKN2/p16 gene in dural hemangiopericytomas, Acta Neuropathol. 91 (1996) 221–225.
[24] L.A. Doyle, M. Vivero, C.D. Fletcher, F. Mertens, J.L. Hornick, Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics, Mod. Pathol. 27 (2014) 390–395. https://doi.org/10.1038/modpathol.2013.164.
[25] E. Dougy, D. Figarella-Branger, P.-E. Morange, A.D. Sandre-Giovannoli, B. Lacarelle, K. Bertaux, K. Pedeillier, N. Saut, C. Jiguet-Jiglaire, S. Tong, K. Achache, The Assistance Publique Hôpitaux de Marseille’s Biobank, Open Journal of Bioresources. 7 (2020) 8. https://doi.org/10.5334/ojb.63.
[26] GeneCards - Human Genes | Gene Database | Gene Search, (n.d.). https://www.genecards.org/ (accessed March 31, 2021).
[27] Home - Gene - NCBI, (n.d.). https://www.ncbi.nlm.nih.gov/gene (accessed March 29, 2020).
[28] C. Kopanos, V. Tsiolkas, A. Kouris, C.E. Chapple, M. Albarca Aguilera, R. Meyer, A. Massouras, VarSome: the human genomic variant search engine, Bioinformatics. 35 (2019) 1978–1980. https://doi.org/10.1093/bioinformatics/bty897.
[29] F. de A. e Lima, UMAP clustering in Python, Poissonisfish. (2020). https://poissonisfish.com/2020/11/14/umap-clustering-in-python/ (accessed March 31, 2021).
[30] L. McInnes, J. Healy, J. Melville, UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction, ArXiv:1802.03426 [Cs, Stat]. (2020). http://arxiv.org/abs/1802.03426 (accessed March 31, 2021).
[31] H. Dufour, P. Métellus, S. Fuentes, X. Murracciole, J. Régis, D. Figarella-Branger, F. Grisoli, Meningeal hemangiopericytoma: a retrospective study of 21 patients with special review of postoperative external radiotherapy, Neurosurgery. 48 (2001) 756–762; discussion 762-763.
[32] J. Aruga, K.J. Millen, ZIC1 Function in Normal Cerebellar Development and Human Developmental Pathology, Adv. Exp. Med. Biol. 1046 (2018) 249–268. https://doi.org/10.1007/978-981-10-7311-3_13.
[33] R. Satow, S. Inagaki, C. Kato, M. Shimozawa, K. Fukami, Identification of zinc finger protein of the cerebellum 5 as a survival factor of prostate and colorectal cancer cells, Cancer Sci. 108 (2017) 2405–2412. https://doi.org/10.1111/cas.13419.
[34] R. Houtmeyers, J. Souopgui, S. Tejpar, Deregulation of ZIC Family Members in Oncogenesis, in: J. Aruga (Ed.), Zic Family: Evolution, Development and Disease, Springer, Singapore, 2018: pp. 329–338. https://doi.org/10.1007/978-981-10-7311-3_16.
[35] R. Satow, T. Nakamura, C. Kato, M. Endo, M. Tamura, R. Batori, S. Tomura, Y. Murayama, K. Fukami, ZIC5 drives melanoma aggressiveness by PDGFD-mediated activation of FAK and STAT3, Cancer Res. (2016). https://doi.org/10.1158/0008-5472.CAN-16-0991.
[36] GABBR2 Gene - GeneCards | GABR2 Protein | GABR2 Antibody, (n.d.). https://www.genecards.org/cgi-bin/carddisp.pl?gene=GABBR2 (accessed August 30, 2020).
[37] M.Ø. Agerbæk, S.R. Bang-Christensen, M.-H. Yang, T.M. Clausen, M.A. Pereira, S. Sharma, S.B. Ditlev, M.A. Nielsen, S. Choudhary, T. Gustavsson, P.H. Sorensen, T. Meyer, D. Propper, J. Shamash, T.G. Theander, A. Aicher, M. Daugaard, C. Heeschen, A. Salanti, The VAR2CSA malaria protein efficiently retrieves circulating tumor cells in an EpCAM-independent manner, Nat Commun. 9 (2018) 3279. https://doi.org/10.1038/s41467-018-05793-2.
[38] S.R. Bang-Christensen, R.S. Pedersen, M.A. Pereira, T.M. Clausen, C. Løppke, N.T. Sand, T.D. Ahrens, A.M. Jørgensen, Y.C. Lim, L. Goksøyr, S. Choudhary, T. Gustavsson, R. Dagil, M. Daugaard, A.F. Sander, M.H. Torp, M. Søgaard, T.G. Theander, O. Østrup, U. Lassen, P. Hamerlik, A. Salanti, M.Ø. Agerbæk, Capture and Detection of Circulating Glioma Cells Using the Recombinant VAR2CSA Malaria Protein, Cells. 8 (2019). https://doi.org/10.3390/cells8090998.
[39] NM_000546 c.743G>T SNV | hg19, (n.d.). https://varsome.com/variant/hg19/NM_000546%20c.743G%3ET (accessed September 1, 2020).
[40] G.P. Dagrada, R.D. Spagnuolo, V. Mauro, E. Tamborini, L. Cesana, A. Gronchi, S. Stacchiotti, M.A. Pierotti, T. Negri, S. Pilotti, Solitary fibrous tumors: loss of chimeric protein expression and genomic instability mark dedifferentiation, Mod. Pathol. 28 (2015) 1074–1083. https://doi.org/10.1038/modpathol.2015.70.
[41] Search of: solitary fibrous tumor - List Results - ClinicalTrials.gov, (n.d.). https://clinicaltrials.gov/ct2/results?recrs=&cond=solitary+fibrous+tumor&term=&cntry=&state=&city=&dist= (accessed March 31, 2021).
[42] C. Apra, A. Alentorn, K. Mokhtari, M. Kalamarides, M. Sanson, Pazopanib efficacy in recurrent central nervous system hemangiopericytomas, J. Neurooncol. 139 (2018) 369–372. https://doi.org/10.1007/s11060-018-2870-0.